Korean drugmaker Celltrion has paid KRW 1 billion ($700,000) to access Pinot Bio’s antibody-drug conjugate (ADC) linker-payload technology. The PINOT-ADC platform, comprising of an independent drug and linker technology, overcomes the resistance limitations of existing ADC drugs, according to developer Pinot Bio. As such, fellow Korean firm Celltrion has tapped up the technology, forging a deal for up to 15 ADC candidates targeting solid tumor cancers using the platform. According to the Korea Biomedical Review, on top of the KRW…

GSK has doubled down on its partnership with Samsung Biologics, inking a deal valued at 26.8% of the Korean CDMO’s 2021 revenues. Details of the contract, released in a regulatory filing today, show that Pharma Giant GlaxoSmithKline has entered into a contract with Samsung Biologics worth KRW 420,667,219,640 ($296 million) beginning October 11 2022 and ending December 31 2030. The deal represents 26.8% of the contract development and manufacturing organization’s (CDMO’s) full year 2021 revenues of KRW 1,568,006,928,039. GSK already…

Nearly two years after buying Prevail Therapeutics, Eli Lilly is doubling down on its gene therapy presence through the acquisition of Akouos. Eli Lilly will pay $12.50 a share for Boston, Massachusetts-based Akouos, equating to around $487 million. The Big Pharma firm could pay a further one contingent value right (CVR) of up to $3 per share, adding another $123 million to the deal. Akouos is developing gene therapies to address hearing loss conditions, with its lead candidate AK-OTOF set…

The collaboration between Inceptor Bio and Avectas will aim to improve the development and production of CAR-T cell therapies for the treatment of solid tumors. Financial details and length of the partnership remain under wraps. However, under the terms of the agreement, Inceptor will use Avectas’ Solupore technology as a substitute to electroporation for engineering T cells with the aim to produce an improved T cell product. In April 2021, Avectas received $8.7 million in funding to develop the cell…

Cevec’s cell line development capabilities are a highly complementary addition to Cytiva’s bioprocessing portfolio, the firm says. The acquisition announced this morning sees Germany’s CEVEC and its 46 staff join bioprocess giant Cytiva for an undisclosed amount. The deal brings Cytiva a range of cell line development and viral vector manufacturing technologies, which Emmanuel Abate, president of Genomic Medicine at Cytiva, told BioProcess Insider will be “highly complementary” to the biomanufacturing tools and services offered by Cytiva and fellow Danaher…

Rocket Pharmaceuticals will gain Renovacor’s program REN-001, an AAV-based gene therapy targeting BAG3-associated dilated cardiomyopathy (DCM) through the acquisition. Under the terms of the deal, Rocket, a firm focused on genetic therapies for rare childhood disorders, has acquired Renovacor, a company aiming to deliver precision therapies for individuals battling genetically-driven cardiovascular and mechanistically-related diseases. Rocket claims that the acquisition strengthens its adeno associated virus (AAV) based cardiac gene therapy leadership and scales the firm’s clinical assets for the treatment of…